Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

Shor Boris; Kahler Jennifer; Dougher Maureen; Xu Jane; Mack Michelle; Rosfjord Ed; Wang Fang; Melamud Eugene; Sapra Puja

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

【24h】

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

机译：与PI3K / mTOR抑制剂或紫杉烷类药物联合使用的抗5T4抗体-药物偶联物的增强的抗肿瘤活性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Targeted treatment of solid or liquid tumors with antibody-drug conjugates (ADCs) can lead to promising clinical benefit. The aim of the study is to investigate combination regimens of auristatin-based ADCs in preclinical models of cancer.

机译：目的：用抗体-药物偶联物（ADC）靶向治疗实体瘤或液体瘤可带来有希望的临床收益。这项研究的目的是研究在临床前癌症模型中基于澳瑞他汀的ADC的联合治疗方案。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第2期|共12页
作者
Shor Boris; Kahler Jennifer; Dougher Maureen; Xu Jane; Mack Michelle; Rosfjord Ed; Wang Fang; Melamud Eugene; Sapra Puja;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes [J] . Shor Boris, Kahler Jennifer, Dougher Maureen, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第2期

机译：与PI3K / mTOR抑制剂或紫杉烷类药物联合使用的抗5T4抗体-药物偶联物的增强的抗肿瘤活性
2. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas [J] . Inaba Kanako, Oda Katsutoshi, Ikeda Yuji, Gynecologic Oncology: An International Journal . 2015,第2期

机译：PI3K / mTOR抑制剂SAR245409和选择性MEK1 / 2抑制剂pimasertib联合使用对子宫内膜癌的抗肿瘤活性
3. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models [J] . Yiqing Qu, Xiuxiu Wu, Yunhong Yin, Journal of experimental & clinical cancer research : . 2014,第1期

机译：选择性MEK1 / 2抑制剂AZD6244联合PI3K / mTOR抑制剂BEZ235在耐吉非替尼的NSCLC异种移植模型中的抗肿瘤活性
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma [O] . Ming-Huang Chen, Kun-Chun Chiang, Chi-Tung Cheng, 2014

机译：HSP90抑制剂和PI3K / mTOR双重抑制剂联合使用对胆管癌的抗肿瘤活性
7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells [O] . Martinelli Erika, Troiani Teresa, DAiuto Elena, 2013

机译：pimasertib（一种选择性的MEK 1/2抑制剂）与PI3K / mTOR抑制剂或多靶点激酶抑制剂联合在耐pimasertib的人肺癌和大肠癌细胞中的抗肿瘤活性

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

摘要

著录项

相似文献

相关主题

期刊订阅